Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360195 | 0.92 | NISCH (0.40) | NISCHPDCD1LG2CD274LMNATDP1 | |
| SCHEMBL4070597 | 0.90 | NISCH (0.51) | NISCHPDCD1LG2CD274 | |
| SCHEMBL4365248 | 0.87 | NISCH (0.41) | NISCHLMNATSHR | |
| SCHEMBL4819055 | 0.85 | NISCH (0.45) | NISCHLMNATSHR | |
| SCHEMBL4164278 | 0.85 | NISCH (0.40) | NISCHLMNATSHR | |
| SCHEMBL4824334 | 0.81 | NISCH (0.43) | NISCH | |
| SCHEMBL4362402 | 0.79 | MC4R (0.44) | NISCHPDCD1LG2CD274LMNA | |
| SCHEMBL4073703 | 0.79 | NISCH (0.53) | NISCHLMNAMAPK1TSHR | |
| SCHEMBL4362157 | 0.78 | MC4R (0.45) | NISCHPDCD1LG2CD274LMNAS1PR1 | |
| SCHEMBL4369445 | 0.78 | NISCH (0.46) | NISCHPDCD1LG2CD274TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | claimed |
| WO-2009080351-A1 | COMPOUNDS WITH ANTI-EMETIC EFFECT | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2072050-A1 | Compounds with anti-emetic effect | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-06-24 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1644337-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Gene Logic, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1204645-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001010842-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885PDCD1LG2 1529/4885CD274 1713/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | NISCH 2500/4885PDCD1LG2 1037/4885CD274 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.